文献速递免疫规划卫生政策与健康促进慢病防控与筛查

荷兰老年人接种高剂量流感疫苗的成本效果:纳入对呼吸系统与心血管住院的影响

Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations.
PubMed 文献 · Vaccine · 2024-04-17

本研究评估荷兰60岁及以上成人由标准剂量四价流感疫苗(SD-QIV)转为高剂量疫苗(HD-QIV)的成本效果。采用终身 horizon 的健康经济模型,从社会视角比较两种策略,并基于近期Meta分析纳入心肺住院等获益。结果显示HD-QIV按标价具有成本效果,ICER为每获得一个QALY需5400欧元,主要驱动因素为预防心肺住院。

要点

  • 荷兰60岁及以上成人中,HD-QIV相比SD-QIV的ICER为每QALY 5400欧元。
  • 在荷兰20000欧元/QALY的支付意愿阈值下,HD-QIV具有成本效果的概率达100%。
  • HD-QIV的成本效果主要来自预防心肺住院,另有减少全科医生就诊和死亡等公共卫生获益。

核心结论

  • 在荷兰现有流感疫苗接种运动中,对60岁及以上成人实施HD-QIV具有高度成本效果。
  • HD-QIV可能有助于缓解荷兰医院冬季呼吸道季节的潜在容量问题。

研究设计与样本

  • 采用健康经济模型,比较实施HD-QIV与当前标准SD-QIV两种情景。
  • 模型采用终身 horizon,从社会视角评估成本效果。
  • 使用近期发表的Meta分析纳入HD-QIV的获益(包括心肺住院),分析分别考虑仅RCT或结合RCT与RWE估计的情景分析。
  • 目标人群为荷兰60岁及以上成人。

主要发现

  • 实施HD-QIV按标价具有成本效果,ICER为每获得一个QALY需5400欧元。
  • 上述结果的主要驱动因素为预防心肺住院。
  • 其他公共卫生获益包括预防全科医生就诊和死亡。
  • HD-QIV具有高度成本效果的可能性,在荷兰20000欧元/QALY的支付意愿阈值下达到100%的概率。

关键数值与推荐

  • ICER为每QALY 5400欧元(HD-QIV vs SD-QIV)。
  • 荷兰支付意愿阈值为每QALY 20000欧元。
  • 在该阈值下HD-QIV具有成本效果的概率为100%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We assess the cost-effectiveness of switching from standard-dose quadrivalent influenza vaccination (SD-QIV) to high-dose vaccination (HD-QIV) for Dutch adults aged 60 years and older. METHODS: A health-economic model was used to compare the scenario where HD-QIV was implemented compared to the current standard, SD-QIV. This model used a lifetime horizon and assessed the cost-effectiveness from a societal perspective. A recently published meta-analysis was used to incorporate the benefits of HD-QIV, including cardiorespiratory hospitalizations, in analyses considering RCT only or combining RCT and RWE estimates in a scenario analysis. RESULTS: Implementing HD-QIV is cost effective at its list price, with an ICER of €5,400 per QALY gained. The main driver of these results is the prevention of cardiorespiratory hospitalizations. Other public health benefits are the prevention of GP consults and deaths. HD-QIV is highly likely to be cost-effective, reaching a 100% probability of being cost effective at the Dutch willingness-to-pay threshold of €20,000 per QALY. CONCLUSIONS: Implementing HD-QIV for adults aged 60 and over within the existing influenza vaccination campaign is highly cost effective. HD-QIV may support alleviating potential capacity issues in Dutch hospitals in the winter respiratory season.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. van der Pol S, Zeevat F, Postma MJ, et al. Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations. Vaccine. 2024. PMID: 38631948. doi:10.1016/j.vaccine.2024.04.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。